Home Newsfeeds RBC Capital Reiterates Outperform on Verisk Analytics, Maintains $210 Price Target

RBC Capital Reiterates Outperform on Verisk Analytics, Maintains $210 Price Target

RBC Capital analyst Ashish Sabadra reiterates Verisk Analytics (NASDAQ:VRSK) with a Outperform and maintains $210 price target.

byBenzinga Newsdesk

March 15, 2023

1 minute read

RBC Capital analyst Ashish Sabadra reiterates Verisk Analytics (NASDAQ:VRSK) with a Outperform and maintains $210 price target.

Leafbuyer Technologies Shares Soar 17% On Earnings Release

By Vuk Zdinjak

September 29, 11:50 AM

Leafbuyer Technologies, Inc (OTCQB: LBUY) annual revenue was $3.8 million, a 43% increase compared to $2.66 million in the previous year.

LBUY

Wells Fargo Maintains Equal-Weight on Zoom Video Comms, Lowers Price Target to $95

By Benzinga Newsdesk

August 23, 7:24 AM

Wells Fargo analyst Michael Turrin maintains Zoom Video Comms (NASDAQ:ZM) with a Equal-Weight and lowers the price target from $105 to $95.

Analyst Ratings

Demystifying Chesapeake Energy: Insights From 6 Analyst Reviews

By Benzinga Insights

January 3, 11:01 AM

During the last three months, 6 analysts shared their evaluations of Chesapeake Energy (NASDAQ:CHK), revealing diverse outlooks from…

CHK

Marinus Pharmaceuticals Receives Positive Committee For Medicinal Products For Human Use Opinion For ZTALMY For The Adjunctive Treatment Of Seizures Associated With CDKL5 Deficiency Disorder

By Happy Mohamed

May 26, 8:13 AM

The European Commission decision is expected within 67 days of the CHMP opinion Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat

MRNS

RBC Capital Reiterates Outperform on Verisk Analytics, Maintains $210 Price Target

Related Posts

Leafbuyer Technologies Shares Soar 17% On Earnings Release

Wells Fargo Maintains Equal-Weight on Zoom Video Comms, Lowers Price Target to $95

Demystifying Chesapeake Energy: Insights From 6 Analyst Reviews

Marinus Pharmaceuticals Receives Positive Committee For Medicinal Products For Human Use Opinion For ZTALMY For The Adjunctive Treatment Of Seizures Associated With CDKL5 Deficiency Disorder